DeepX Diagnostics announced today that it received FDA clearance for its DermoSight digital dermatoscope. The DermoSight scope is used for teledermatology screening of suspect skin cancer lesions. Washington-based DeepX Diagnostics plans to enter the U.S. market having already completed more than 180,000 assessments in Europe. FDA clearance for DermoSight covers the acquisition of skin lesions […]